Current Report
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 30, 2005
Callisto
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-32325
|
13-3894575
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File
Number)
|
(IRS
Employer Identification
No.)
|
|
420
Lexington Avenue, Suite 1609
|
New
York, New York
10170
|
(Address
of principal executive offices)
|
Registrant’s
telephone number, including area code: (212) 297-0010
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
|
|
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On
June 30, 2005, the Board of Directors of Callisto Pharmaceuticals, Inc.,
a
Delaware corporation ("Callisto"), pursuant to a unanimous written consent
of
the Board of Directors elected Riccardo Dalla-Favera, M.D., a director of
Callisto to serve until the next annual meeting of the stockholders of Callisto
and/or until his successor has been duly elected and qualified.
Dr.
Dalla-Favera has been Director of the Herbert Irving Comprehensive Cancer
Center
at Columbia University since early 2005, Director for the Institute for Cancer
Genetics at Columbia University since 1999 and Professor in the Department
of
Genetics & Development at Columbia University since 1992. Dr. Dalla-Favera
was formerly Deputy Director of Columbia-Presbyterian Cancer Center from
1992 to
1998. Dr. Dalla-Favera received his M.D., magna cum laude from the University
of
Milan, Italy and served his residency in hematology at the University of
Milan.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
July 7,
2005
|
|
|
|
CALLISTO
PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/
Gary S. Jacob |
|
|
|
Gary
S. Jacob, Ph.D.
Chief
Executive Officer
|